Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Sep;35(9):1925–1927. doi: 10.1128/aac.35.9.1925

In vitro susceptibility of Brucella melitensis to antibiotics.

E Rubinstein 1, R Lang 1, B Shasha 1, B Hagar 1, L Diamanstein 1, G Joseph 1, M Anderson 1, K Harrison 1
PMCID: PMC245295  PMID: 1952869

Abstract

The in vitro susceptibilities of 86 recent clinical isolates of Brucella melitensis to minocycline, streptomycin, co-trimoxazole, rifampin, and six fluoroquinolones were determined. Minocycline exhibited the lowest MIC and was followed by rifampin and streptomycin. Among the quinolones, WIN 57273 and ciprofloxacin were the most active agents. No antibiotic combination of these agents exhibited synergy against 15 selected isolates. In killing rate experiments, streptomycin exhibited the most rapid kill (less than 12 h), while a complete kill with minocycline, rifampin, and ciprofloxacin was delayed up to 48 h. The combinations of streptomycin with each of minocycline, rifampin, or ciprofloxacin exhibited the fastest kills (within 2 h), while with the other combinations, a complete kill was delayed up to 96 h. These results demonstrate the discrepancy between the results of various in vitro methods in evaluating the antibiotic susceptibility of B. melitensis.

Full text

PDF
1925

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ariza J., Bosch J., Gudiol F., Liñares J., Viladrich P. F., Martín R. Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis. Antimicrob Agents Chemother. 1986 Dec;30(6):958–960. doi: 10.1128/aac.30.6.958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ariza J., Gudiol F., Pallarés R., Rufí G., Fernández-Viladrich P. Comparative trial of co-trimoxazole versus tetracycline-streptomycin in treating human brucellosis. J Infect Dis. 1985 Dec;152(6):1358–1359. doi: 10.1093/infdis/152.6.1358. [DOI] [PubMed] [Google Scholar]
  3. Bosch J., Liñares J., López de Goicoechea M. J., Ariza J., Cisnal M. C., Martin R. In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis. J Antimicrob Chemother. 1986 Apr;17(4):459–461. doi: 10.1093/jac/17.4.459. [DOI] [PubMed] [Google Scholar]
  4. Cisneros J. M., Viciana P., Colmenero J., Pachón J., Martinez C., Alarcón A. Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks plus streptomycin for 2 weeks. Antimicrob Agents Chemother. 1990 May;34(5):881–883. doi: 10.1128/aac.34.5.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Farrell I. D., Hinchliffe P. M., Robertson L. Sensitivity of Brucella spp to tetracycline and its analogues. J Clin Pathol. 1976 Dec;29(12):1097–1100. doi: 10.1136/jcp.29.12.1097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gutiérrez Altés A., Díez Enciso M., Peña García P., Campos Bueno A. In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline, and co-trimoxazole. Antimicrob Agents Chemother. 1982 Mar;21(3):501–503. doi: 10.1128/aac.21.3.501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hall W. H., Manion R. E. In vitro susceptibility of Brucella to various antibiotics. Appl Microbiol. 1970 Oct;20(4):600–604. doi: 10.1128/am.20.4.600-604.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hooper D. C., Wolfson J. S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985 Nov;28(5):716–721. doi: 10.1128/aac.28.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Khan M. Y., Dizon M., Kiel F. W. Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis. Antimicrob Agents Chemother. 1989 Aug;33(8):1409–1410. doi: 10.1128/aac.33.8.1409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Philippon A. M., Plommet M. G., Kazmierczak A., Marly J. L., Nevot P. A. Rifampin in the treatment of experimental brucellosis in mice and guinea pigs. J Infect Dis. 1977 Oct;136(4):481–488. [PubMed] [Google Scholar]
  11. Qadri S. M., Akhtar M., Ueno Y., al-Sibai M. B. Susceptibility of Brucella melitensis to fluoroquinolones. Drugs Exp Clin Res. 1989;15(10):483–485. [PubMed] [Google Scholar]
  12. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES